Robert Thurman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Robert Thurman has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Devra J. Olson
Pfizer, Inc., Bothell, Washington
22 shared publications - Kelly M. Hensley
Seagen Inc., Bothell, Washington
22 shared publications - Michelle Ulrich
Seagen Inc., Bothell, Washington
22 shared publications - Sean Allred
Seagen Inc., Bothell, Washington
22 shared publications - Albina Nesterova
Seagen Inc., Bothell, Washington
19 shared publications - Anthony Cao
Seagen Inc., Bothell, Washington
19 shared publications
Latest Publications
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
Antibody humanization, binding assays, conjugation, mass spec, additional in vivo details
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
Antibody humanization, binding assays, conjugation, mass spec, additional in vivo details
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Data from SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
SGN-CD228A is an investigational antibody–drug conjugate (ADC) directed to melanotransferrin (CD228, MELTF, MFI2, p97), a cell-surface protein first identified in melanoma. SGN-CD228A consists of a humanized antibody, hL49, with high specificity and affinity for CD228 that is stably conjugated to 8 molecules of the clinically validated microtubule-disrupting agent monomethyl auristatin E (MMAE) via a novel glucuronide linker. We performed comprehensive IHC studies, which corroborated published RNA sequencing data and confirmed low CD228 expression in normal tissues and high expression in several cancers, including melanoma, squamous non–small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), colorectal cancer, and pancreatic cancer. SGN-CD228A was efficiently internalized in various tumor cell types, and its cytotoxic activity was dependent on CD228 expression and internalization and intrinsic sensitivity to the MMAE payload. Compared with the valine-citrulline dipeptide linker, the novel glucuronide linker increased the cellular retention of MMAE in vitro and conferred improved antitumor activity against melanoma cell lines in vitro and in vivo. In addition, SGN-CD228A was active across melanoma, TNBC, and NSCLC cell line- and patient-derived xenograft models with heterogeneous antigen expression. In vivo, CD228 expression was important for response to SGN-CD228A but was not well correlated across all tumor types, suggesting that other factors associated with ADC activity are important. Overall, SGN-CD228A is a CD228-directed, investigational ADC that employs innovative technology and has compelling preclinical antitumor activity. SGN-CD228A is investigated in a Phase I clinical trial (NCT04042480) in patients with advanced solid tumors.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
SGN-CD228A is an investigational antibody–drug conjugate (ADC) directed to melanotransferrin (CD228, MELTF, MFI2, p97), a cell-surface protein first identified in melanoma. SGN-CD228A consists of a humanized antibody, hL49, with high specificity and affinity for CD228 that is stably conjugated to 8 molecules of the clinically validated microtubule-disrupting agent monomethyl auristatin E (MMAE) via a novel glucuronide linker. We performed comprehensive IHC studies, which corroborated published RNA sequencing data and confirmed low CD228 expression in normal tissues and high expression in several cancers, including melanoma, squamous non–small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), colorectal cancer, and pancreatic cancer. SGN-CD228A was efficiently internalized in various tumor cell types, and its cytotoxic activity was dependent on CD228 expression and internalization and intrinsic sensitivity to the MMAE payload. Compared with the valine-citrulline dipeptide linker, the novel glucuronide linker increased the cellular retention of MMAE in vitro and conferred improved antitumor activity against melanoma cell lines in vitro and in vivo. In addition, SGN-CD228A was active across melanoma, TNBC, and NSCLC cell line- and patient-derived xenograft models with heterogeneous antigen expression. In vivo, CD228 expression was important for response to SGN-CD228A but was not well correlated across all tumor types, suggesting that other factors associated with ADC activity are important. Overall, SGN-CD228A is a CD228-directed, investigational ADC that employs innovative technology and has compelling preclinical antitumor activity. SGN-CD228A is investigated in a Phase I clinical trial (NCT04042480) in patients with advanced solid tumors.
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity
Supplementary Figure S4. pIRE, pJNK, and CHOP upregulation in lymphoma lines treated with brentuximab vedotin or MMAE
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity
Supplementary Figure S4. pIRE, pJNK, and CHOP upregulation in lymphoma lines treated with brentuximab vedotin or MMAE
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S6 from Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity
Supplementary Figure S6. Brentuximab vedotin’s multifaceted mechanism of action
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity
Supplementary Figure S6. Brentuximab vedotin’s multifaceted mechanism of action
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity
Supplementary Figure S2. ICD hallmarks observed from tumor cell lines treated with brentuximab vedotin or MMAE
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity
Supplementary Figure S2. ICD hallmarks observed from tumor cell lines treated with brentuximab vedotin or MMAE
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity
Supplementary Figure S3. Raw pixel intensities for western blots in Figure 2
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity
Supplementary Figure S3. Raw pixel intensities for western blots in Figure 2
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity
Supplementary Figure S1. Overview of ICD
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity
Supplementary Figure S1. Overview of ICD
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S5 from Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity
Supplementary Figure S5. Brentuximab vedotin enhances cytotoxic T-cell infiltration into LCL tumors
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity
Supplementary Figure S5. Brentuximab vedotin enhances cytotoxic T-cell infiltration into LCL tumors